Marke

Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results

Clinical guidelines from the disciplines of cardiology and laboratory and emergency medicine have all emphasized the importance of cardiac markers in diagnosing or ruling out acute myocardial infarction. The measurement of cardiac troponins is especially useful in the large fraction of patients presenting with acute coronary syndrome (ACS) who have...

Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures

EAST HANOVER, N.J.--(BUSINESS WIRE)--Jul 11, 2007 - Since the May2007 release of a New England Journal of Medicine (NEJM) reportthat Avandia users are 43 percent more likely to suffer a heartattack and 67 percent more likely to die of cardiovascular causesthan non-users of Avandia, it is no surprise that physicians intendto switch many type 2 diabetes patients from Avandia to therapiesbelie...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM)Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today reported that new data werepresented on the comparative Phase III clinical trial evaluating aVELCADE based therapy in newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes

-- Additional Findings Reported on Glucose Homeostasis Effects inNormal and Diabetic Rats -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,Phase IIa study of the safety profile of multiple doses of theinvestigational compound dapagliflozin, a selective inhibitor ofthe Sodium-Glucose Transporter 2 (SGLT2) administered alone orconcomitantly with metformin in subjects with Typ...

New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research andMarkets (http://www.researchandmarkets.com/reports/c60415) hasannounced the addition of Looking at Chiral Technologies to theiroffering. The advancements in molecular research and continued untiringefforts of the research industry to develop better more preciselyapplicable Pharmaceuticals as well as agro compounds would have not...

Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

- New Data from Open-Label Study Presented at Federation ofClinical Immunology Societies (FOCIS) Annual Meeting - CARLSBAD, Calif., June 11, 2007 /PRNewswire-FirstCall/ --Orchestra Therapeutics, Inc. (Bulletin Board: OCHT) announced todaypositive new data from its completed Phase II open-label study ofNeuroVax(TM), an investigational T Cell Receptor (TCR) peptidevaccine for the treatment...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential fornew option to improve convenience for patients - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today announced the presentation of positivedata for VELCADE, the market-leading therapy for patients withmultiple myeloma (MM) who have received at least one prior therapy.These data include resu...

Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.(NASDAQ: INGN) and the Company's clinical collaborators todayreported updated Phase 2 data demonstrating a significantcorrelation between abnormal p53, tumor responses and increasedsurvival following ADVEXIN(R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were prese...

Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data

CHAPEL HILL, N.C., May 25, 2007 /PRNewswire/ -- With enormousinvestments and the success of a pharmaceutical product at play,pharmaceutical firms need to develop effective strategies forcommunicating clinical trial results early. Companies that mastertheir communication planning and execution will gain a significantadvantage in the marketplace. According to research and consulting...

New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace

First comprehensive study of market dynamics offers insights intowhat will be needed to get new, faster and better TB drugs topatients NEW YORK, May 14, 2007 /PRNewswire-USNewsire/ -- The GlobalAlliance for TB Drug Development (TB Alliance), a not-for-profit,product development partnership accelerating the discovery anddevelopment of new TB drugs, today released results from the firstcom...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced datafrom two preclinical studies, one identifying a functionalbiomarker for its novel histone deacetylase (HDAC) inhibitor andanother demonstrating preclinical anti-tumor activity with itsBruton's tyrosine kinase (BTK) inhibitor compounds. The data werepresented at the American...

Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection

- Findings Published in Blood Highlight Millennium Leadership inPersonalized Medicine and Could Strengthen the Role of VELCADE asFoundation of Therapy in Broad Range of Multiple Myeloma Patients - CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-FirstCall/ --Findings published in the April 15th issue of Blood show that ateam of researchers led by Millennium Pharmaceuticals, Inc. hasdiscovered...

Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - Introgen Therapeutics,Inc. (NASDAQ:INGN) reported updated ADVEXIN(R) biomarker data overthe weekend in Los Angeles, California at the Annual Meeting of theAmerican Association for Cancer Research. Abnormality of the p53 tumor suppressor is one of the mostcommon and fundamental molecular defects in cancer. ADVEXIN'smechanism of action is targete...

DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy

EVRY, France, April 12, 2007 /PRNewswire/ -- DNA TherapeuticsS.A. an emerging pharmaceutical company specialized in innovativecancer therapy announces today the elucidation of a new mechanismof action and the identification of a biomarker of itsfirst-in-class antitumoral lead molecule Dbait. It will bepresented at the forecoming American Association for CancerResearch annual meeting 2007...